Reports Q3 revenue $47.7M, consensus $49.15M. “We are very pleased with the lead indicators of the initial market response to our commercial launch of Fanapt in bipolar I disorder, a testament to the strong clinical evidence and the strength of our commercial strategy, and we look forward to continuous growth in the coming quarters. In parallel, we have launched Ponvory for multiple sclerosis and we are looking forward to increased prescriber and patient awareness in the near future. We expect Fanapt, milsaperidone and Fanapt LAI to form a diverse and expanding psychiatry franchise for years to come,” said Mihael Polymeropoulos, CEO. “On the research and development front, we are focused on completing in the coming months our New Drug Applications for tradipitant in motion sickness and for milsaperidone in schizophrenia and bipolar I disorder. IND filings are expected to be completed for Ponvory in ulcerative colitis and psoriasis later this quarter. We are committed to growing our revenue from our existing products and continuing to diversify our sources of revenue through indication expansion and new product development.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Vanda Pharmaceuticals initiated with a Buy at H.C. Wainwright
- Is VNDA a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz